EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Open-Label Placebo Effects in Reducing Depression Severity Among Adults with Major Depressive Disorder: A Systematic Review and Meta-Analysis of Early Evidence

Janet Mercedes Arévalo-Ipanaqué, Maria Leticia Gobo Silva, Ricardo Romero-Vucovich, Gianluca Conte, Matheus Gerhard Rosenfeld, Sergio José Fausto Girón, Lisa Gonzalez, Jordy Batista, Sofia Ines Volpi, Maximiliano Espinosa, Daniela Lorena Alvarado Rodriguez, Salvatore Minnella und 15 weitere

Principles and Practice of Clinical Research Journal · 26.04.2026 · 11 (4)

DOI: 10.21801/ppcrj.2025.114.3 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Principles and Practice of Clinical Research Journal, online erschienen am 26.04.2026. Verfasst von Janet Mercedes Arévalo-Ipanaqué und 26 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Open-label placebo (OLP) represents an intervention where patients knowingly receive inert treatments associated with clinical benefits. This approach has demonstrated efficacy across multiple medical conditions. Meanwhile, major depressive disorder (MDD) affects 280 million people worldwide, yet three-quarters receive no treatment, urging non-pharmacological approaches. Despite this high prevalence, there is scarce data on the potential of OLP intervention for MDD. Our objective is to determine whether OLP can meaningfully reduce depression scores in adults with MDD.

Methods

Following Cochrane methodology and PRISMA guidelines, six databases were systematically reviewed including studies from up to May 5, 2025. Inclusion criteria encompassed randomized controlled trials (RCTs) examining OLP interventions in adults with MDD, measuring depression severity using validated scales. Studies were independently screened by multiple reviewers. Risk of bias was assessed using RoB2. A meta-analysis was conducted using post-intervention mean scores and standard deviations.

Results

From 1,886 screened records, 3 randomized controlled trials (n=118; mean age 46.8 years; 78% female) met the inclusion. Trials were conducted in the USA, Israel, and Austria between 2012 and 2022, with sample sizes ranging from 20–60 participants. All compared open-label placebo (OLP) to treatment-as-usual or waitlist controls, using validated depression scales (HAM-D-17, QIDS-SR, BDI-II). Individual trial findings were mixed: one trial found significant symptom reduction with OLP plus cognitive-behavioral therapy, though the effect was small; two trials reported no overall between-group differences, although one showed improvement in patients with early-onset depression. A meta-analysis of two small trials at 4 weeks suggested a modest reduction in depressive symptoms favoring OLP (Hedges's g=−0.43, 95% CI −0.83 to −0.04), although both individual trials were underpowered and did not reach statistical significance. Given the limited number of studies and high risk of bias, these findings should be interpreted as preliminary. Risk of bias was rated as some concerns in one study and high in two, primarily due to outcome measurement and missing data.

Conclusions

Current evidence from three small RCTs suggests that open-label placebo may be associated with modest short-term symptom improvement in adults with MDD; however, the evidence base is limited, heterogeneous, and at risk of bias. These findings should be considered preliminary and hypothesis-generating, and larger, methodologically rigorous trials are required before clinical recommendations can be made.

Zitieren

APA

Arévalo-Ipanaqué, J. M., Silva, M. L. G., Romero-Vucovich, R., Conte, G., Rosenfeld, M. G., Girón, S. J. F., Gonzalez, L., Batista, J., Volpi, S. I., Espinosa, M., Rodriguez, D. L. A., Minnella, S., Ulloa, T. L., Seguic, N. A., Allegretti, Y. H., Laureano, J. A. D. L. R., Bermudez, C. C., Koyama, L. W., Souza, M. E. N. D., …, & Jawhar, W. (2026). Open-Label Placebo Effects in Reducing Depression Severity Among Adults with Major Depressive Disorder: A Systematic Review and Meta-Analysis of Early Evidence. Principles and Practice of Clinical Research Journal, 11(4). https://doi.org/10.21801/ppcrj.2025.114.3

Vancouver

Arévalo-Ipanaqué JM, Silva MLG, Romero-Vucovich R, Conte G, Rosenfeld MG, Girón SJF, et al. Open-Label Placebo Effects in Reducing Depression Severity Among Adults with Major Depressive Disorder: A Systematic Review and Meta-Analysis of Early Evidence. Principles and Practice of Clinical Research Journal. 2026;11(4). doi:10.21801/ppcrj.2025.114.3

BibTeX
@article{ArvaloIpanaqu2026,
  author = {Arévalo-Ipanaqué, Janet Mercedes and Silva, Maria Leticia Gobo and Romero-Vucovich, Ricardo and Conte, Gianluca and Rosenfeld, Matheus Gerhard and Girón, Sergio José Fausto and Gonzalez, Lisa and Batista, Jordy and Volpi, Sofia Ines and Espinosa, Maximiliano and Rodriguez, Daniela Lorena Alvarado and Minnella, Salvatore and Ulloa, Tadeus Lopez and Seguic, Nadine Aranis and Allegretti, Yazmin Heredia and Laureano, Johan Antonio De La Rosa and Bermudez, Cristian Camilo and Koyama, Letícia Watanabe and Souza, Maria Eduarda Nabhan de and Althobaiti, Somaya and Gamonal, Karen and Adeyemi, Folasade Mary and Lorenzana, Luis Pedro and Sheriff, Aderibigbe Adeniyi and Benedek, Peter and Vilorio-Alvarez, Emilio and Jawhar, Wajih},
  title = {Open-Label Placebo Effects in Reducing Depression Severity Among Adults with Major Depressive Disorder: A Systematic Review and Meta-Analysis of Early Evidence},
  journal = {Principles and Practice of Clinical Research Journal},
  year = {2026},
  volume = {11},
  number = {4},
  doi = {10.21801/ppcrj.2025.114.3}
}
Kostenlos starten →